Jazz Pharmaceuticals PLC to Post FY2022 Earnings of $25.40 Per Share, Svb Leerink Forecasts (NASDAQ:JAZZ)

Share on StockTwits

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – Analysts at Svb Leerink lifted their FY2022 earnings per share estimates for shares of Jazz Pharmaceuticals in a research report issued on Tuesday, November 5th. Svb Leerink analyst A. Fadia now anticipates that the specialty pharmaceutical company will post earnings per share of $25.40 for the year, up from their previous forecast of $25.33. Svb Leerink also issued estimates for Jazz Pharmaceuticals’ FY2023 earnings at $21.22 EPS.

A number of other equities analysts have also weighed in on the stock. Evercore ISI reaffirmed a “buy” rating on shares of Jazz Pharmaceuticals in a research note on Monday, August 12th. Oppenheimer set a $176.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, September 26th. TheStreet lowered shares of Jazz Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Friday, October 18th. Piper Jaffray Companies lowered shares of Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $205.00 to $142.00 in a research note on Wednesday, August 21st. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $147.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, August 8th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and nine have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $165.71.

JAZZ stock traded up $4.18 during trading on Friday, hitting $130.14. The company had a trading volume of 747,500 shares, compared to its average volume of 551,936. The stock has a market cap of $7.24 billion, a price-to-earnings ratio of 10.63, a PEG ratio of 1.57 and a beta of 1.09. The company has a quick ratio of 3.52, a current ratio of 3.71 and a debt-to-equity ratio of 0.58. Jazz Pharmaceuticals has a 12 month low of $113.52 and a 12 month high of $154.44. The firm has a 50-day moving average price of $124.77 and a 200-day moving average price of $131.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings data on Tuesday, November 5th. The specialty pharmaceutical company reported $4.10 earnings per share for the quarter, topping the consensus estimate of $3.19 by $0.91. Jazz Pharmaceuticals had a net margin of 29.61% and a return on equity of 28.57%. The firm had revenue of $537.70 million during the quarter, compared to analysts’ expectations of $523.92 million. During the same quarter in the previous year, the company posted $3.58 EPS. Jazz Pharmaceuticals’s revenue was up 14.6% on a year-over-year basis.

Several institutional investors have recently bought and sold shares of JAZZ. Denali Advisors LLC acquired a new position in shares of Jazz Pharmaceuticals during the 2nd quarter worth about $584,000. WINTON GROUP Ltd lifted its stake in Jazz Pharmaceuticals by 218.8% in the 2nd quarter. WINTON GROUP Ltd now owns 4,942 shares of the specialty pharmaceutical company’s stock valued at $705,000 after purchasing an additional 3,392 shares during the last quarter. Centric Wealth Management acquired a new stake in Jazz Pharmaceuticals in the 2nd quarter valued at about $884,000. Xact Kapitalforvaltning AB lifted its stake in Jazz Pharmaceuticals by 10.3% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 14,922 shares of the specialty pharmaceutical company’s stock valued at $2,127,000 after purchasing an additional 1,389 shares during the last quarter. Finally, CENTRAL TRUST Co lifted its stake in Jazz Pharmaceuticals by 256.4% in the 2nd quarter. CENTRAL TRUST Co now owns 1,522 shares of the specialty pharmaceutical company’s stock valued at $210,000 after purchasing an additional 1,095 shares during the last quarter. Institutional investors own 87.71% of the company’s stock.

In other news, SVP Paul Treacy sold 4,371 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $137.40, for a total transaction of $600,575.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bruce C. Cozadd sold 500 shares of the stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $130.00, for a total transaction of $65,000.00. Following the transaction, the chief executive officer now owns 311,855 shares of the company’s stock, valued at $40,541,150. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 5,371 shares of company stock valued at $730,575. Company insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Read More: What is Forex?

Earnings History and Estimates for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Jazz Pharmaceuticals PLC to Post FY2022 Earnings of $25.40 Per Share, Svb Leerink Forecasts
Jazz Pharmaceuticals PLC to Post FY2022 Earnings of $25.40 Per Share, Svb Leerink Forecasts
Brokerages Set Installed Building Products Inc  PT at $58.18
Brokerages Set Installed Building Products Inc PT at $58.18
Analysts Set LHC Group, Inc.  Price Target at $130.18
Analysts Set LHC Group, Inc. Price Target at $130.18
SHIN ETSU CHEM/ADR  Upgraded to Sell at ValuEngine
SHIN ETSU CHEM/ADR Upgraded to Sell at ValuEngine
United Rentals  Rating Increased to Conviction-Buy at Goldman Sachs Group
United Rentals Rating Increased to Conviction-Buy at Goldman Sachs Group
Selecta Biosciences  Issues Quarterly  Earnings Results
Selecta Biosciences Issues Quarterly Earnings Results


 
© 2006-2019 Zolmax.